ASCCP Management Guidelines2.4.3 - App Store

The ASCCP Risk-Based Management Consensus Guidelines provide evidence-based recommendations for managing abnormal cervical cancer screening results and cancer precursors, including post-colposcopy and post-treatment scenarios.

ASCCP is pleased to offer this app to streamline navigation of the ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The guidelines articles, as published in the Journal of Lower Genital Tract Disease, as well as the comprehensive risk estimates, can be accessed through https://www.asccp.org/guidelines.

These evidence-based management guidelines, initially developed in 2019, came together through a consensus process of 19 organizations. The updated management guidelines aim to:
. Allow for a more complete and precise estimation of risk
. Provide more appropriate intervention for high-risk individuals (detect and treat more precancer)
. Recommend less intervention for low-risk individuals (decrease testing and treatment that won’t prevent cancer and may cause reproductive harm)
. Allow for the future addition of new risk modifiers and screening and management technologies

See https://www.asccp.org/UserGuide for tips on using the app.

Version History - Updated language to clarify follow up information
- Patch fix for new iOS release 2.4.3 Jul 15 - Updated screening section 2.4.2 Jun 25 Incorporates HPV Self-Collection Recommendations 2.4.1 Mar 4 Incorporates HPV Self-Collection Recommendations 2.4 10/30/2025 Extended HPV Genotyping Support. 2.3 07/31/2025 Expanded post-colposcopy guidance and updated ASC-US cotest recommendations. 2.2 06/28/2025 Dual Stain Management:
We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making.

SmartUI Enhancement:
Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points. 2.1.1 03/17/2025 Dual Stain Management:
We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making.

SmartUI Enhancement:
Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points. 2.1 02/01/2025 Dual Stain Management:
We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making.

SmartUI Enhancement:
Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points. 2.0.1 10/11/2024 Dual Stain Management:
We’ve introduced enhanced support for managing Dual Stain results, providing a streamlined approach for more accurate analysis and decision-making.

SmartUI Enhancement:
Our updated SmartUI now intelligently guides you through patient history, enabling faster, more efficient recommendations based on key data points. 2.0 10/10/2024 Recommendation updates based on new erratum publication. 1.7 02/24/2022 Minor improvements to management recommendations and typographical errors 1.6 11/25/2021 New Clinical Situations tree to aide in navigation.
Expanded app to include Screening Guidelines. 1.5 09/24/2021 New 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors provide new recommendations. 1.3 04/09/2021 New 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors provide new recommendations. 1.2 10/01/2020 New 2019 ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors provide new recommendations. 1.1 08/19/2020 1.0 06/05/2020